← Back to home

FOLATE RECEPTOR-ALPHA POSITIVE PLATINUM-RESISTANT HIGH-GRADE SEROUS EPITHELIAL OVARIAN CANCER

Clinical trials for FOLATE RECEPTOR-ALPHA POSITIVE PLATINUM-RESISTANT HIGH-GRADE SEROUS EPITHELIAL OVARIAN CANCER explained in plain language.

Never miss a new study

Get alerted when new FOLATE RECEPTOR-ALPHA POSITIVE PLATINUM-RESISTANT HIGH-GRADE SEROUS EPITHELIAL OVARIAN CANCER trials appear

Sign up with your email to follow new studies for FOLATE RECEPTOR-ALPHA POSITIVE PLATINUM-RESISTANT HIGH-GRADE SEROUS EPITHELIAL OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Real-World check: targeted drug MIRV tested against tough ovarian cancer

Disease control Not yet recruiting

This study monitors the safety and effectiveness of mirvetuximab soravtansine (MIRV) in people with a specific type of ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy and tests positive for the folate receptor-alpha…

Matched conditions: FOLATE RECEPTOR-ALPHA POSITIVE PLATINUM-RESISTANT HIGH-GRADE SEROUS EPITHELIAL OVARIAN CANCER

Sponsor: AbbVie • Aim: Disease control

Last updated Jul 09, 2026 00:00 UTC

FOLATE RECEPTOR-ALPHA POSITIVE PLATINUM-RESISTANT HIGH-GRADE SEROUS EPITHELIAL OVARIAN CANCER

Get alerted when new FOLATE RECEPTOR-ALPHA POSITIVE PLATINUM-RESISTANT HIGH-GRADE SEROUS EPITHELIAL OVARIAN CANCER trials appear

Real-World check: targeted drug MIRV tested against tough ovarian cancer